Marcin Kubeczko, MD at Maria Sklodowska-Curie National Research Institute of Oncology, shared a post on LinkedIn:
“My sixth SABCS — with six posters!
But this is certainly not my achievement alone.
Huge thanks to the outstanding teams whose work I had the pleasure of presenting — especially Clinic Barcelona Comprehensive Cancer Center, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), REVEAL GENOMICS, and Hospital 12 Octubre, with special thanks to Aleix Prat and Fara Brasó Maristany.
I am also deeply grateful to Maria Sklodowska Curie National Research Institute of Oncology and to the teams from Poland, the Czech Republic, and Slovakia forming the Central European Breast Cancer Collaboration (CEBCC), led by Mirosława Püsküllüoğlu.
Truly a privilege to be part of such inspiring collaborations.
Key scientific messages from the presented work:
- HER2DX: The ERBB2 score, now validated in an independent cohort, confirmed strong prognostic value for long-term outcomes in MBC. The novel HER2DX metastatic prognostic score provided additional prognostic information beyond ERBB2, supporting its role in treatment decision-making.
- Radiotherapy combined with SG: The addition of RT appeared safe, without increased toxicity or treatment discontinuation. Survival differences likely reflected higher disease burden, particularly CNS involvement.
- G-CSF prophylaxis during SG: Primary prophylaxis reduced grade ≥3 neutropenia but was not associated with improved survival or reduced febrile neutropenia. Dose reductions due to AEs did not adversely affect survival.
- SG in mTNBC with brain metastases: SG showed clinically meaningful activity with a manageable safety profile. Outcomes were comparable or numerically favorable to ASCENT BM subgroup data, with no clear impact of BM number or size.
- SG after pembrolizumab-based therapy in mTNBC: In a real-world cohort of 303 patients, no clear loss of efficacy or safety was observed. However, the impact of prior anti-PD-1 exposure remains clinically relevant and warrants further investigation as treatment paradigms evolve.
- Histopathology in de novo HER2-positive MBC treated with TPH: Histological grade emerged as an independent prognostic factor, while ER status and Ki67 were not significant. While histopathology offers valuable prognostic insights, molecular profiling holds the potential to deliver a deeper biological understanding and enables more precise treatment stratification in this heterogeneous disease.”
More from SABCS 2025.